Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children
NCT ID: NCT03518710
Last Updated: 2018-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
15 participants
INTERVENTIONAL
2018-08-31
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional Imaging and Reading Deficit in Children With NF1
NCT02422732
Reading Disability in Children With NF1
NCT02397967
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
NCT01851135
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
NCT05377008
Non-invasive Stimulation in Neurofibromatosis Type 1
NCT03310996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Children with NF1
One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :
* Neuropsychological evaluation
* Evaluation of the reading assistance technique
Neuropsychological evaluation
Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:
* Process evaluation:
* Oculomotors: DEM test (5min)
* Visuo-attention: computerized STROOP (15min)
* Visuo-Perceptive: DTVP3 (30min)
* Phonological \& lexical: Exalang (10min)
Evaluation of the reading assistance technique
Evaluation of the reading assistance technique (about 30 min) and comprising:
\- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neuropsychological evaluation
Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:
* Process evaluation:
* Oculomotors: DEM test (5min)
* Visuo-attention: computerized STROOP (15min)
* Visuo-Perceptive: DTVP3 (30min)
* Phonological \& lexical: Exalang (10min)
Evaluation of the reading assistance technique
Evaluation of the reading assistance technique (about 30 min) and comprising:
\- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 7 and 9 years old child in 1st - 3rd grades with 5 children/grade
* Informed children and written consent obtained from one of the parents or other lawful representative
* Child who is covered by the social security scheme
Exclusion Criteria
* associated neurological disorder such as brain tumors or epilepsy
* mental retardation (IQ \<70 or Wechsler Intelligence Scale for Children (WISC) scores SIM et IC \< 7)
* children with Autism Spectrum Disorder
* diagnosis of attention deficit hyperactivity disorder (ADHD) (DSM-IV), with presence of hyperactive-impulsive or inattentive symptom
* pharmaceutical treatment (e.g., anti-depressants, anxiolytics)
7 Years
9 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yves Chaix, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Toulouse
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02907-46
Identifier Type: OTHER
Identifier Source: secondary_id
RC31/17/0376
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.